Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: George the Greek who wrote (554)	6/10/2003 2:12:19 PM
From: Icebrg	Respond to of 897

>> Since you say no one in their right mind would buy at $10, why have these institutional investors put money into this private placement?>> They have shorted the stock, taken delivery of the new stock from the private placement and pocketed the difference. An easy way to make some money. There has been no news to motivate the price rise. The stock is not worth more now than it was a month ago. Why should anyone take the risks investing in this company? >>How would this news change the instinct to short this stock, at the $12 level?>> Not at all. The stock will fall back again, regardless . >>Regarding the technology, VTAs: is this the same as anti-angiogenesis tech?>> Oxigene have their own version. They used to have BMY as a partner, but they returned the product rights.

To: George the Greek who wrote (554)	6/10/2003 3:35:21 PM
From: tuck	Read Replies (1) \| Respond to of 897

George, My understanding is that VTA is a bit different in that it targets existing vasculature in tumors, rather than trying to prevent its growth as in antiangiogenesis. VTA attempts to starve the tumors blood vessels. The OXGN thread is so dead that SI can't find it anymore, but it is still viewable, if not easily locatable by SI's search engine. It is the repository of some good discussion. Subject 11430 Cheers, Tuck